PharmTech Drug Digest 11.20

Manufacturing

Latest News


Review of SUT Adoption in Biopharma Manufacturing

The evolution of therapeutic modalities drives the adoption of single-use technologies.

Review of SUT Adoption in Biopharma Manufacturing

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Automating the Future of Fill/Finish

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

 Automating the Future of Fill/Finish

Latest Videos


Shorts

Do You Need New Excipients for Continuous Manufacturing
0:18
Do You Need New Excipients for Continuous Manufacturing
12 hours ago
by
Pauline van der Wijst-Janssen
Working in Parellel for Serialization
0:23
Working in Parellel for Serialization
a day ago
by
Terry Katz
Drug shortages now last 5+ years and the root cause isn’t on the manufacturing floor.
0:28
Is Reshoring the Answer for the Supply Chain?
6 days ago
by
Zachary Zubulake(+1 more)
Drug shortages now last 5+ years and the root cause isn’t on the manufacturing floor.
0:33
How To Fix A Broken Supply Chain
8 days ago
by
Zachary Zubulake(+1 more)
Drug shortages now last 5+ years and the root cause isn’t on the manufacturing floor.
0:46
Why Drug Shortages Are Getting Harder To Fix
9 days ago
by
Zachary Zubulake(+1 more)
Manish Baviskar, senior validation engineer, Hubot CDMO
0:35
The Checklist to Validate AI in GMP Enviorments
12 days ago
by
Manish Baviskar
Manish Baviskar, senior validation engineer, Hubot CDMO
0:46
AI vs. Traditional Software in Pharma
15 days ago
by
Manish Baviskar
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
0:31
New Solutions to the Drug Recall Crisis
22 days ago
by
Zachary Zubulake(+2 more)
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
1:01
How to Stop the Next Nitrosamine Drug Recall
24 days ago
by
Zachary Zubulake(+2 more)
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
0:42
The Hidden Danger in Generic Antidepressants
a month ago
by
Zachary Zubulake

More News